Advertisement

Topics

Generex combines AE37 with Merck’s Keytruda in Phase II trial for TNBC

19:00 EDT 1 Aug 2017 | Net Resources International

Generex Biotechnology has signed a clinical trial collaboration agreement through its Antigen Express division to combine its cancer vaccine AE37 with Merck’s Keytruda (pembrolizumab) in a Phase II clinical trial for patients with triple-negative bre…

Original Article: Generex combines AE37 with Merck’s Keytruda in Phase II trial for TNBC

NEXT ARTICLE

More From BioPortfolio on "Generex combines AE37 with Merck’s Keytruda in Phase II trial for TNBC"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...